Table 5.
Femoral Trabecular Parameters: Anticatabolic Therapies
| Group | Femoral Tb.N | Femoral Tb.Th | Femoral Tb.Sp | |||
|---|---|---|---|---|---|---|
| VEH: WT/Nmp4−/− | 0.91 ± 0.23/1.18 ± 0.09 | 0.046 ± 0.006/0.045 ± 0.003 | 0.331 ± 0.023/0.285 ± 0.011 | |||
| ALN: WT/Nmp4−/− | 1.17 ± 0.25/1.14 ± 0.29 | 0.051 ± 0.006/0.046 ± 0.004 | 0.302 ± 0.007/0.294 ± 0.023 | |||
| ZOL: WT/Nmp4−/− | 1.38 ± 0.38/1.47 ± 0.47 | 0.052 ± 0.003/0.049 ± 0.007 | 0.316 ± 0.032/0.282 ± 0.029 | |||
| RAL: WT/Nmp4−/− | 1.21 ± 0.36/1.74 ± 0.13 | 0.060 ± 0.003/0.059 ± 0.005 | 0.313 ± 0.023/0.274 ± 0.011 | |||
| Anticatabolic therapy | G: | P = 0.0024 | G: | P = 0.0701 | G: | P < 0.0001 |
| T: | P < 0.0001 | T: | P < 0.0001 | T: | P < 0.2017 | |
| GxT: | P = 0.0306 | RAL | A | GxT: | P = 0.04 | |
| Nmp4−/− RAL | A | ZOL | B | WT VEH | A | |
| Nmp4−/− ZOL | AB | ALN | B | WT ZOL | AB | |
| WT ZOL | AB | VEH | B | WT RAL | AB | |
| WT RAL | BC | GxT: | P = 0.22 | WT ALN | ABC | |
| Nmp4−/− VEH | BC | Nmp4−/− ALN | BC | |||
| WT ALN | BC | Nmp4−/− VEH | BC | |||
| Nmp4−/− ALN | BC | Nmp4−/− ZOL | BC | |||
| WT VEH | C | Nmp4−/− RAL | C | |||
The micro-CT analyses of the femoral architecture in mice treated with the anticatabolic therapies. The data were analyzed using two-way analyses of variance using genotype and treatment as the independent variables. Statistical significance was set at P ≤ 0.05, and levels not connected by the same letter are significantly different. The data represent mean ± standard deviation, n = 7 to 12 mice per group.
Abbreviations: G, genotype; T, treatment.